Oppenheimer Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00

Keros Therapeutics (NASDAQ:KROS) had its price objective lowered by Oppenheimer from $63.00 to $23.00 in a research report sent to investors on Thursday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Several other analysts have also weighed in on KROS. HC Wainwright decreased their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Guggenheim lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, December 16th. Finally, TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Stock Up 3.2 %

Keros Therapeutics stock opened at $10.86 on Thursday. The business has a 50 day moving average price of $36.37 and a two-hundred day moving average price of $47.13. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The stock has a market cap of $439.94 million, a price-to-earnings ratio of -2.08 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.33) EPS. On average, analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in shares of Keros Therapeutics by 6.8% in the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after buying an additional 32,492 shares during the last quarter. Barclays PLC increased its stake in shares of Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after buying an additional 35,022 shares during the period. Intech Investment Management LLC bought a new stake in shares of Keros Therapeutics during the third quarter worth $603,000. Finally, Point72 Asset Management L.P. lifted its stake in shares of Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares during the period. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.